Clinical Trials Logo
  1. Home
  2. MGMT-Unmethylated Glioblastoma
  3. NCT05033587

Study of AK105 With Anlotinib and Radiotherapy Adjuvant Therapy in MGMT Unmethylated Newly Diagnosed Glioblastoma.

MGMT-Unmethylated Glioblastoma Clinical Trial

Official title:
AK105 With Anlotinib and Radiotherapy Adjuvant Therapy in MGMT Unmethylated Newly Diagnosed Glioblastoma: a Prospective, Open-label Single-arm, Exploratory Trial.

Clinical Trial Summary

This is a prospective, open-label single-arm, exploratory, two-stage design trial, aiming to investigate safety and efficacy of AK105 with anlotinib and radiotherapy adjuvant therapy in MGMT unmethylated newly diagnosed glioblastoma.

Clinical Trial Description

Glioblastoma is the most common and aggressive primary brain tumor in adults. Treatment usually involves surgery, after which chemotherapy and radiation therapy are used. The Central Brain Tumor Registry of the United States (CBTRUS) Statistical Report primary brain and other central nervous system tumors diagnosed in the United States in 2012-2016, glioblastoma accounted for 48.3% of primary malignant brain tumors. The Stupp protocol has become standard of care for the treatment of newly diagnosed GBM, however, some MGMT unmethylated glioblastomas are still resistant to temozolomide. Immunotherapy is being studied as treatment for the cancer, AK105 is a humanized monoclonal antibody that specially binds to PD-1. Anlotinib hydrochloride is a multi-target receptor tyrosine kinase inhibitor. Based on the mechanism study, tumor vascular abnormalities promote tissue hypoxia and increase lactic acid, thereby activating immunosuppression and inhibiting T cell function. Anti-angiogenic drugs enhance the infiltration of effector immune cells by inducing normalization of blood vessels and reducing immunosuppression. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05033587
Study type Interventional
Source The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Contact Mi Yang, Dr.
Phone +86-25-83106666
Email yangmi@nju.edu.cn
Status Recruiting
Phase Phase 2
Start date September 2021
Completion date November 1, 2023
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04396860 - Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma Phase 2/Phase 3
Recruiting NCT05879250 - WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Phase 2
Recruiting NCT06186401 - Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells Phase 1
Terminated NCT03250299 - Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Phase 1
Recruiting NCT03107780 - Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer Phase 1
Recruiting NCT05909618 - Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases Phase 2
Recruiting NCT04725214 - Anlotinib Combined With STUPP for MGMT Nonmethylated Glioblastoma Phase 2
Not yet recruiting NCT05694416 - Etoposide Plus Cisplatin Compared With Temozolomide in Patients With Glioblastoma Phase 2
Recruiting NCT04224441 - Repurposing Chlorpromazine in the Treatment of Glioblastoma Phase 2
Recruiting NCT05236036 - Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma Phase 1
Active, not recruiting NCT03452930 - Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated Glioblastoma Phase 1